Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
NCT ID: NCT03373968
Last Updated: 2026-01-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2/PHASE3
206 participants
INTERVENTIONAL
2017-10-24
2029-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
NCT02851797
Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy
NCT05933057
A Study Evaluating the Real-World Experience of Givinostat in Patients With Duchenne Muscular Dystrophy
NCT07127978
A Study to Assess Safety/Tolerability, pk, Effects on Histology, Clinical Parameters of Givinostat in Children With DMD
NCT01761292
Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Becker Muscular Dystrophy
NCT03238235
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
As weight affects GIVINOSTAT exposures, the dosage will be modified based on subject weight according the rules detailed in the study protocol section 11.2.2.1.
In addition, in case a subject will have a consistent (e.g., at least 2 consecutive evaluations) platelets count ≤150 x 10\^9/L and not meet the stopping criteria for platelets, the Investigator will have to reduce the dose of 1/3 or 20% less of the current dose as described in the study protocol section 10.5.1.3. During the first month of treatment, platelets count assessment will be performed weekly, while during the second month it will be performed every 2 weeks, in order to strictly monitor this parameter for safety reasons, with the exclusion of subjects coming from study DSC/11/2357/43 for which the first visit will be 4 months after the Visit 1/baseline visit.
Study drug should be permanently interrupted if any of the following occurs:
* severe drug-related diarrhoea (i.e., increase of ≥7 stools per day);
* any drug-related SAE;
* QTcF \>500 msec;
* platelets count ≤50 x 10\^9/L;
* white blood cells ≤2.0 x 10\^9/L;
* hemoglobin ≤8.0 g/dL; To avoid laboratory errors and anomalous values, test must be confirmed with a repeated test performed on the next working day. The treatment should be stopped until the retest result becomes available. If the repeated test is still under the stopping limit value, study drug must be permanently discontinued. If the repeated test is acceptable, the subject can resume treatment.
The Investigator will follow up the patient until resolution or acceptable stabilization of the event occurs and document all the relevant information, as applicable. After the resolution/stabilization of the event, the subject will be withdrawn from the study and the EOS Visit (see Section 12.1.10) will be performed.
Any decision relevant to the dose adjustment and/or modification of schedule of assessments can be discussed with the Medical Monitor, but the final decision remains with the Investigator only or its authorized designee.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
givinostat
Givinostat oral suspension (10 mg/mL) twice daily in a fed state
Givinostat
suspension of givinostat (10 mg/mL)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Givinostat
suspension of givinostat (10 mg/mL)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* had a baseline vastus lateralis muscle fat fraction (VL MFF) assessed by MRS in the range ≤5% or \>30%, i.e. included in"off-target" group,
* never been randomized because, the enrollment in the off target group was completed.
2. Aged ≥6 years old;
3. Are able to give informed assent and/or consent in writing signed by the subject and/or parent/legal guardian (according to localregulations);
4. Subjects must be willing to use adequate contraception:
* Contraceptive methods must since the previous GIVINOSTAT study through 3 months after the last dose of study drug, and include the following:
* True abstinence (absence of any sexual intercourse), when in line with the preferred and usual lifestyle of the subject.
* Periodic abstinence (e.g. calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception.
* Condom with spermicide and the female partner must use an acceptable method of contraception, such as an oral,
* transdermal, injectable or implanted steroid-basedcontraceptive, or a diaphragm or a barrier method of contraception in conjunction with spermicidal jelly such asfor example cervical cap with spermicide jelly.
Exclusion Criteria
2. Use of any current investigational drug other than Givinostat;
3. Have presence of other clinically significant disease, which, in the Investigator's opinion, could adversely affect the safety of the subject, making it unlikely that the course of treatment or follow-up would be completed, or could impair the assessment of study results;
4. Have a diagnosis of other uncontrolled neurological diseases or presence of relevant uncontrolled somatic disorders that are not related to DMD;
5. Have platelets count, White Blood Cell and Hemoglobin at screening \< Lower Limit of Normal (LLN)\* (for abnormal screening laboratory test results (\<LLN), the platelets count, White Blood Cell and Hemoglobin will be repeated once; if the repeat test result is still \<LLN, then exclusionary);
6. Have Triglycerides \> 300 mg/dL (3.42 mmol/L) in fasting condition at screening visit\* (for abnormal screening laboratory test results (\>300 mg/dL), the triglycerides will be repeated once; if the repeat test result is still \>300 mg/dL, then exclusionary);
7. Have inadequate renal function, as defined by serum Cystatin C \>2 x the upper limit of normal (ULN) at screening visit\*. If the value is \>2 x ULN, the serum Cystatin C will be repeated once; if the repeated test result is still \>2 x ULN, the subject should be excluded);
8. Have heart failure (New York Heart Association Class III or IV)
9. Have a current liver disease or impairment, including but not limited to an elevated total bilirubin\* (i.e. \> 1.5 x ULN), unless secondary to Gilbert disease or pattern consistent with Gilbert's;
10. Have a baseline QTcF \>450 msec, (as the mean of 3 consecutive readings 5 minutes apart) or history of additional risk factors for torsades de pointes (e.g., heart failure, hypokalemia, or family history of long QT syndrome);
11. Have a psychiatric illness/social situation rendering the potential subject unable to understand and comply with the muscle function tests and/or with the study protocol procedures.
12. Have any hypersensitivity to the components of study medication;
13. Have a sorbitol intolerance or sorbitol malabsorption or have the hereditary form of fructose intolerance.
7 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cromsource
INDUSTRY
Italfarmaco
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California - Davis Medical Center - Devis Physical Medicine & Rehabilitation
Sacramento, California, United States
Rady Children's Hospital center - UCSD Department of Neuroscience
San Diego, California, United States
Connecticut Children's Medical Center, Neurology Division
Hartford, Connecticut, United States
Child Health Research Institute
Gainesville, Florida, United States
MD Rare Disease Research, LLC
Atlanta, Georgia, United States
University of Iowa Children's Hospital
Iowa City, Iowa, United States
Washington University School of Medicine in St Louis Department of Neurology 660 S.Euclid Avenue, Campus Box 8111
St Louis, Missouri, United States
Shriners Hospitals for Children
Portland, Oregon, United States
The Children's Hospital of Philadelphia Colket Translational Research Building
Philadelphia, Pennsylvania, United States
Virginia Commonwealth University Childrens Hospital of Richmond at
Richmond, Virginia, United States
University Hospitals Leuven, Neuromuscular Reference Centre, Child Neurology
Leuven, , Belgium
Hospital de La Citadelle, Centre de Référence des Maladies Neuromuscolaires (CRMN)
Liège, , Belgium
Kinsmen Research Centre - Alberta Children's Hospital
Calgary, Alberta, Canada
The University of British Columbia, Children's and Womens Health Centre of BC Branch
Vancouver, British Columbia, Canada
Holland Bloorview Kids Rehabilitation Hospital
Toronto, Ontario, Canada
CHU de Nantes - Hotel-Dieu - Hopital Nord Laennec, rez-de-chausse haut ail Ouest
Nantes, , France
Hôpital Armand Trousseau I-Motion - Plateforme d'essais cliniques pédiatriques Bâtiment Lemariey - Porte 20 * 2ème étage 26 Avenue du Dr Arnold Nette
Paris, , France
Universitätsklinikum Essen - Kinder-und Jugendmedizin Neuropadiatrie
Essen, , Germany
Klinik- und Poliklinik fur Kinder- und Jugendmedizin, Universitatsklinikum HamburgEppendorf, Martinistr. 52
Hamburg, , Germany
Klinikum der Universitat Munchen, Campus Innenstadt, Lindwurmstr. 4
München, , Germany
Institute of Neurology - Schneider Children's Medical Center of Israel Kaplan, 14
Petah Tikva, , Israel
U.O.S.D. Centro Traslazionale di Miologia e Patologie Neurodegenerative, Building 16 - ground floor IRCCS Istituto Giannina Gaslini,
Genova, , Italy
A.O.U. Policlinico G. Martino, U.O.C. Neurologia e Malattie Neuromuscolari
Messina, , Italy
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, UOS di Neurologia Pediatrica
Milan, , Italy
IRCCS Istituto Neurologico Carlo Besta
Milan, , Italy
Centro Clinico NeMO Fondazione Serena ONLUS Area SUD
Milan, , Italy
Ospedale Pediatrico Bambino Gesù, Malattie Neuromuscolari e Neurodegenerative
Roma, , Italy
Fondazione Policlinico Universitario "A.Gemelli", UOC Neuropsichiatria Infantile
Roma, , Italy
Leiden University Medical Center LUMC, Albinusdreef 2
Leiden, , Netherlands
Radboud University Medical Centre
Nijmegen, , Netherlands
Clinic of Neurology and Psychiatry for Children and Youth - Neurology Department Dr. Subotic 6a,
Belgrade, , Serbia
Neuromuscular Pathology Unit - Hospital Sant Joan de Déu
Esplugues de Llobregat, Barcellona, Spain
Hospital Materno-Infantil
Barcelona, , Spain
Hospital Universitario Virgen del Rocio
Seville, , Spain
Hospital Universitari i Politècnic La Fe - Servicio Neurologia
Valencia, , Spain
Alder Hey Children's Hospital NHS Trust
Liverpool, UK, United Kingdom
The Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust
Gobowen, , United Kingdom
UCL Great Ormond Street Institute of Child Health, Dubowitz Neuromuscular Centre and MRC Centre for NMD
London, , United Kingdom
The John Walton Muscular Dystrophy Research Centre
Newcastle upon Tyne, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
McDonald CM, Guglieri M, Vucinic D, Acsadi G, Brandsema JF, Bruno C, Finanger EL, Harper A, Lobato ML, Masson R, Muelas N, Munell F, Nevo Y, Pereon Y, Phan H, Sansone VA, Scoto M, Willis T, Finkel RS, Vandenborne K, Cazzaniga S, Montrasio S, Alessi F, Bettica P, Mercuri E; Givinostat Study 51 Investigators; Cooperative International Neuromuscular Research Group (CINRG) Duchenne Natural History Study (DNHS) Investigators; ImagingDMD Investigators. Long-Term Evaluation of Givinostat in Duchenne Muscular Dystrophy, and Natural History Comparisons. Ann Clin Transl Neurol. 2025 Nov;12(11):2335-2348. doi: 10.1002/acn3.70165. Epub 2025 Aug 19.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DSC/14/2357/51
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.